| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/29/2008 | WO2008063959A1 Vaccination of horses against lawsonia intracellularis |
| 05/29/2008 | WO2008063911A2 Cash tracking system |
| 05/29/2008 | WO2008063898A2 Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist |
| 05/29/2008 | WO2008063849A2 Multiple sclerosis therapy |
| 05/29/2008 | WO2008063837A2 Dendritic cell tumor injection therapy and related vaccine |
| 05/29/2008 | WO2008063776A2 Antibodies to lymphotoxin-alpha |
| 05/29/2008 | WO2008063639A2 Compositions and methods for preserving cells of the eye |
| 05/29/2008 | WO2008063555A2 Methods of enhancing immune response using electroporation-assisted vaccination and boosting |
| 05/29/2008 | WO2008063421A2 Biodegradable t-cell activation device and methods |
| 05/29/2008 | WO2008063382A2 Antagonists of pcsk9 |
| 05/29/2008 | WO2008063291A2 Polypeptide ligands for targeting cartilage and methods of use thereof |
| 05/29/2008 | WO2008063213A2 Uses and compositions for treatment of psoriatic arthritis |
| 05/29/2008 | WO2008063147A2 Anthrax polypeptide binding |
| 05/29/2008 | WO2008063129A1 Use of lipid containing particles comprising quillaja saponins for the treatment of cancer |
| 05/29/2008 | WO2008062699A1 Carrier |
| 05/29/2008 | WO2008062288A2 Poly-tlr antagonist |
| 05/29/2008 | WO2008062063A1 Novel antiproliferation antibodies |
| 05/29/2008 | WO2008061953A1 Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto |
| 05/29/2008 | WO2008061950A1 Use of clostridium perfringens type c bacterium for the manufacture of a vaccine |
| 05/29/2008 | WO2008061939A1 Recombinant modified vaccinia virus ankara (mva)-based vaccine for the avian flu |
| 05/29/2008 | WO2008061392A1 Method for preparing cell populations with anti-tumor immune response activity |
| 05/29/2008 | WO2008061377A1 Novel receptor for cd40l and uses thereof |
| 05/29/2008 | WO2008061303A1 Method of treatment and prophylaxis |
| 05/29/2008 | WO2008042261A3 Anti-anthrax antibody, formulations thereof, and methods of use |
| 05/29/2008 | WO2008039390A3 Compositions and methods for chitosan enhanced immune response |
| 05/29/2008 | WO2008038127A3 Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use |
| 05/29/2008 | WO2008011571A9 Polypeptides with reduced susceptibility to oxidation and methods of making |
| 05/29/2008 | WO2008009960A9 Anti-testosterone antibodies |
| 05/29/2008 | WO2007120766A3 Erythropoietin receptor agonists |
| 05/29/2008 | WO2007120693A3 Targeted binding agents directed to upar and uses thereof |
| 05/29/2008 | WO2007114979A3 Gene disruptons, compositions and methods relating thereto |
| 05/29/2008 | WO2007113665A3 Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides |
| 05/29/2008 | WO2007103468A3 Use of vx-702 for treating rheumatoid arthritis |
| 05/29/2008 | WO2007042884A9 Vaccines and methods to treat canine influenza |
| 05/29/2008 | WO2007034210A8 Deglycosylated anti-muc-1 antibodies and uses thereof |
| 05/29/2008 | WO2006137597A9 Novel physiological substance nesfatin, substance relevant thereto, and use of the substances |
| 05/29/2008 | US20080125576 Protein isolation |
| 05/29/2008 | US20080125457 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders |
| 05/29/2008 | US20080125391 administering to a mammal harboring a tumor which expresses HALRs, a Sindbis virus vector to treat the tumor, and the vector has not been modified to target a tumor-specific cellular determinant, has a preferential affinity for HALRs, a Sindbis virus E2 HALR binding domain; ganciclovir; gene therapy |
| 05/29/2008 | US20080125390 Methods for Modulating Immune and Inflammatory Responses |
| 05/29/2008 | US20080125374 Gd3-mimetic peptides |
| 05/29/2008 | US20080125367 Agents for treatment of HCV and methods of use |
| 05/29/2008 | US20080124803 cDNA Corresponding to the antigenome of nonsegmented negative stranded RNA viruses and process for the production of such viruses |
| 05/29/2008 | US20080124763 Constructs and methods for expression of recombinant proteins in methylotrophic yeast cells |
| 05/29/2008 | US20080124743 Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (u1) |
| 05/29/2008 | US20080124739 Compositions and methods for the diagnosis and treatment of tumor |
| 05/29/2008 | US20080124396 polymer synthesized by a cross-coupling reaction of polymer scaffold units and xenoantigens |
| 05/29/2008 | US20080124380 Contacting male ejaculate, prior to contact with a female egg, with an effective anti-fertility amount of a pharmaceutical composition, which comprises an antibody that binds a surface exposed epitope of SP22, and a pharmaceutically acceptable carrier |
| 05/29/2008 | US20080124366 Methods and Compositions for Treating Tumors |
| 05/29/2008 | US20080124365 Using single-stranded DNA template to generate antisense RNA sequences for treatment and prevention of viral infection and cell proliferative disorders; viricides; antitumor agents |
| 05/29/2008 | US20080124364 Recombinant Plasmid and Method for Expressing Hepatitis B Viral Antigens and Virions in Vivo |
| 05/29/2008 | US20080124363 Nucleotide sequences coding enzymatic polypeptide for use in treatment and prevention of parasitic infections |
| 05/29/2008 | US20080124362 Domain II Mutants Of Anthrax Lethal Factor |
| 05/29/2008 | US20080124361 consisting essentially of: a flagellin adjuvant comprising, consisting of, or consisting essentially of a flagellin N-terminal constant region; a flagellin C-terminal constant region; and a Yersinia pestis antigen between the N-terminal constant region and the C-terminal constant region |
| 05/29/2008 | US20080124360 Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes |
| 05/29/2008 | US20080124359 Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease |
| 05/29/2008 | US20080124358 Chemically conjugating a peptide of interest to a heterologous peptide that has been expressed on the coat protein of a cowpea mosaic virus to generate a conjugate and administering the conjugate to a host animal to increase the level of TH1-type immune response |
| 05/29/2008 | US20080124357 vector may contain at least one heterologous nucleic acid molecule(s), expresses in vivo in the animal VSV antigen(s), immunogen(s) or epitope(s) thereof, e.g., VSV G protein and/or VSV N protein and/or VSV M protein |
| 05/29/2008 | US20080124356 Keratinocyte Culturing Method and the Use Thereof |
| 05/29/2008 | US20080124355 live attenuated bacterial strains including Salmonella that express one or more avian influenza antigens for use in live vaccine compositions that can be orally administered |
| 05/29/2008 | US20080124354 Her-2 protein fragments, recombinant peptides comprising same, nucleotide molecules encoding same, recombinant vaccine vectors and immunogenic compositions comprising same, and methods for inducing immune response and treating cancer, comprising same |
| 05/29/2008 | US20080124353 Proteinase k resistant surface protein of neisseria meningitidis |
| 05/29/2008 | US20080124352 Methods to bypass CD4+ cells in the induction of an immune response |
| 05/29/2008 | US20080124351 Proteinase k resistant surface protein of neisseria meningitidis |
| 05/29/2008 | US20080124350 Nanoparticle-based vaccine delivery system containing adjuvant |
| 05/29/2008 | US20080124349 Method or Use of a Solubilized Glucan Product to Increase Immunostimulation in Animals |
| 05/29/2008 | US20080124348 Immune regulation |
| 05/29/2008 | US20080124347 Insulinotropic peptide conjugate using carrier substance |
| 05/29/2008 | US20080124346 Chimeric metal binding protein for use in prevention and treatment of cancer, diabetes, cardiovascular disease, obesity, metabolic disease, neurodegenerative disease, gastrointestinal disease, autoimmune disease, rheumatological disease and infectious disease. |
| 05/29/2008 | US20080124345 Human epidermal growth factor (HER) binding ligand for use in prevention and treatment of cell proliferative disorders |
| 05/29/2008 | US20080124344 Novel Gene Disruptions, Compositions and Methods Relating Thereto |
| 05/29/2008 | US20080124343 Treatment of Inappropriate Immune Responses |
| 05/29/2008 | US20080124342 Anti-Tnf Alpha Antibodies Which Selectively Inhibit Tnf Alpha Signalling Through The P55R |
| 05/29/2008 | US20080124341 Using immunoglobulin specific to viral transport protein associated with budding to prevent and treat viral diseases |
| 05/29/2008 | US20080124340 Erythropoietin receptor agonists |
| 05/29/2008 | US20080124339 Monoclonal antibody specific to mucosal addressin cell adhesion molecule (MAdCAM) for use in prevention and treatment of inflammatory, gastrointestinal, liver disorders |
| 05/29/2008 | US20080124338 Using mixture comprising immunoglobulin and terminal region of nuclear factor kappa beta as therapeutic tool in treatment of sexually transmitted, ocular, cancer and atherosclerotic disorders |
| 05/29/2008 | US20080124337 Immunoglobulin for use in diagnosis, prevention and treatment of neisserial infection; immunootherapeutics |
| 05/29/2008 | US20080124336 Molecules and Methods for Inhibiting Shedding of KIM-1 |
| 05/29/2008 | US20080124335 Novel Polypeptide and the Use Thereof |
| 05/29/2008 | US20080124334 Isolated Nucleic Acids, Vectors and Host Cells Encoding ErbB3 Antibodies |
| 05/29/2008 | US20080124333 Administering glutamate release inhibitor and glutamate receptor antagonist; antiapoptosis |
| 05/29/2008 | US20080124332 Compositions and methods using anti-cs1 antibodies to treat multiple myeloma |
| 05/29/2008 | US20080124331 Compositions and methods for the diagnosis and treatment of tumor |
| 05/29/2008 | US20080124330 Monoclonal antibody for use in treatment and prevention of cell proliferative disorders; tissue targeted therapy |
| 05/29/2008 | US20080124329 Conditioned Cell Immunization |
| 05/29/2008 | US20080124328 Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| 05/29/2008 | US20080124327 Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| 05/29/2008 | US20080124326 Immunoglobulin composition specific epidermal growth factor receptor for use in treatment of cell proliferative and autoimmune diseases; immunotherapy; tissue targeted therapy |
| 05/29/2008 | US20080124325 Using interleukin-6 receptor specific monoclonal antibody for treatment and prevention of skin disorders |
| 05/29/2008 | US20080124324 Immunoglobulin for use in treatment of inflammation, wound repair and tissue modeling |
| 05/29/2008 | US20080124323 Using fructooligosaccharides as components of probiotics for use in prevention and treatment of infection |
| 05/29/2008 | US20080124322 Activation and inhibition of the immune system |
| 05/29/2008 | US20080124321 ISOLATED BOVINE IgG HEAVY CHAIN PROTEIN AND ITS USE AS AN ANTIMICROBIAL |
| 05/29/2008 | US20080124320 High mobility group box (HMGB) protein which inhibits proinflammatory cytokine cascade for use in prevention and/or treatment of weight loss/obesity disorders |
| 05/29/2008 | US20080124319 Using immunoglobulin agonist to prevent signaling from g protein coupled receptor/melanin concentrating hormone receptor and treat gastrointestinal disorders |
| 05/29/2008 | US20080124318 Using alga probiotic to enhance health and control disease in individuals |
| 05/29/2008 | US20080124317 Diagnos and Treatment of Fibrosis Related Pathology |
| 05/29/2008 | US20080124313 Nucleotide sequences coding methionyl tRNA synthetase protein for use in identifying modulators for prevention and treatment of bacterial infection |
| 05/29/2008 | US20080124303 Exhibits tubercin activity; immune enhancers such as glycyrrhizin (GR), glycyrrhetic acid, and Chinese herbal extracts |